Raymond Hill, Former IMS and InVentiv Health Executive, Joins Medivo’s Board of Directors New York, NY (PRWEB) November 17, 2014 - Medivo, Inc., a leader in lab data analytics, today announced that Raymond Hill has been elected to Medivo’s board of directors. As President of InVentiv Health Clinical, Mr. Hill was instrumental in driving EBITDA growth, reducing attrition, securing key strategic partnerships, and re-positioning the company. As President of IMS Consulting and Services, Mr. Hill spearheaded work in portfolio strategy, pricing and market access, launch excellence, managed markets, sales force effectiveness, and commercial outsourcing. Mr. Hill also served as the CEO of Pharmaceutical Product Development Inc.
According to Sundeep Bhan, CEO of Medivo, Mr. Hill’s expertise will be an invaluable resource to the company. “I’m delighted that Ray will be joining our board of directors. His experience managing both clinically oriented and data oriented firms in the healthcare space will serve us well. I look forward to his counsel on matters relating to healthcare data analytics, understanding pharma needs, improving patient care and the convergence of diagnostics, data and therapy selection.”
Mr. Hill’s appointment expands the Board to 6 directors. Mr. Hill joins the following directors:
Gary Kurtzman, MD, Managing Director, Safeguard Scientifics David Stack, President, CEO and Director of Pacira Pharmaceuticals Joseph B. Volpe III, Managing Director, Merck Global Health Innovation, Global Health Innovation Fund LLC Jason Bhan, MD, Chief Medical Officer, Medivo, Inc. Sundeep Bhan, CEO, Medivo, Inc. “I am excited to be joining the board and advising the team at this most interesting time in healthcare”, said Mr. Hill. “Medivo is doing really innovative things in commercializing lab data. With access to over 30 million patients and over 100 million lab test results, Medivo is discovering actionable insights that can be used to treat the right patients with the right drugs at the right time.”
Mr. Hill is the Executive Chairman of Corrona LLC. He also serves on the Board of IntelliCell Biosciences, Inc., and the not-for-profit organization RowNY. He is a graduate of Cornell University and received a Masters degree from Duke University.
Mr. Hill’s appointment is effective November 12, 2014.
About Medivo
Medivo unlocks the power of lab data to better inform treatment decisions and improve health outcomes. Medivo’s clinical data experts extract proprietary insights from the Medivo Lab Value Exchange™(LVX™), an anonymized patient level clinical database of more than 30 million patients. Medivo helps deliver on the promise of precision medicine by providing decision support on the use of targeted therapeutics. Medivo enables life science companies to build clinical intelligence to optimize their sales and marketing initiatives, while enabling our clinical lab partners to realize the full value of their data assets. Founded in 2010 by healthcare entrepreneurs, Medivo’s investors include Safeguard Scientifics, Inc. (NYSE:SFE) and Merck Global Health Innovation Fund (GHIF). For more information, visit http://www.medivo.com.
vs
SOURCE: IntelliCell BioSciences, Inc.
August 21, 2014 12:54 ET
IntelliCell BioSciences Adds Raymond Hill to Board of Directors NEW YORK, NY--(Marketwired - Aug 21, 2014) - IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stromal vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has added Mr. Raymond Hill to its Board of Directors. Mr. Hill has held a number of senior executive roles in the pharmaceutical industry, including President of InVentiv Clinical, CEO and member of the Board of Directors of PPD, and President of IMS Consulting Group. Earlier on in his career, Mr. Hill was a partner at A.T. Kearney and a consultant at Booz Allen & Hamilton. IntelliCell's Chief Executive Officer, Dr. Steven Victor, remarked, "This is a significant addition to the Board of Directors as Mr. Hill brings substantial experience in the field of FDA clinical trials. Mr. Hill is a valuable asset to the company, especially as IntelliCell is embarking on FDA IND clinical claim studies for Osteoarthritis with Dr. James Andrews as well as exploring clinical studies for Autism and ALS." About IntelliCell Biosciences IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell BioSciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell is also developing technology-licensing agreements with technology developers, universities, and international business entities. Forward-Looking Statements Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
Long Profits....the only Real Truth Seek the FACTS available to ALL as Denial of said Produces Losses
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
